Moreover, while vehicle-treated Apcmin/+ mice developed only low-grade adenomas, the Apcmin/+ mice treated with the JTE013 inhibitor broadened high-grade adenomas and carcinomas (Fig. 3g), corroborating the loss of S1PR2 as an accelerator of tumor development and de-differentiation. Here, S1PR2 is linked to adenoma.